KAZIA THERAPEUTICS-SPON ADR (KZIA)

US48669G1058 - ADR

0.37  0 (0%)

After market: 0.3887 +0.02 (+5.05%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
15.225M
22,999.61%		2.09K
-99.99%		22.56K
979.43%		22.5M
99,634.04%
EBITDA
YoY % growth
N/AN/AN/A6.18MN/AN/AN/AN/AN/A
EBIT
YoY % growth
-6.338M
47.75%		-25.382M
-300.46%		-24.125M
4.95%		4.14M
117.16%
Operating Margin
-41.63%-1,214,456.46%-106,934.97%18.40%
EPS
YoY % growth
N/AN/AN/A0.01

All data in AUD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in AUD

Recent Earnings VS Estimates Surprises (AUD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.19
78.19%		-0.05-0.14-272.55%
Q4 2022
Q2Q % growth		 -0.87 -0.10-0.77-753.92%
Recent Revenue VS Estimates Surprises (AUD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 22.42K
20,281.82%		23.46K-1.04K-4.43%
Q4 2022
Q2Q % growth		 110
-100.00%		518.16K-518.05K-99.98%
Q2 2021
Q2Q % growth		 30.82K
-5.34%		1.522M-1.492M-97.98%
Q2 2020
Q2Q % growth		 32.56K
12.94%		1.522M-1.49M-97.86%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A 0% 0%
RevenueN/A N/A 0% 0%